Business
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced that it will donate $3 million to Conquer Cancer®, the ASCO Foundation, to
About this update from Novocure Limited
[{"type":"text","content":" ROOT, Switzerland--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) today announced that it will donate $3 million to Conquer Cancer®, the ASCO Foundation, to advance cancer research and education.\n\n\nConquer Cancer is a global community of advocates, patients, doctors, researchers, caregivers, and others dedicated to improving the lives of people affected by cancer. Its mission is to accelerate breakthroughs in lifesaving research and empower people everywhere to conquer cancer.\n\n\nSince 1984, Conquer Cancer has raised more than $500 million to fund research, education, and quality programs. The nonprofit organization’s grants and awards support clinical and translational cancer research done by gifted physician-scientists at every stage of their careers, from the best and brightest among young investigators to senior researchers providing mentorship opportunities for the next generation of cancer researchers.\n\n\nNovocure will disburse $1 million annually to Conquer Cancer through 2025. Conquer Cancer will use the funding in support of cancer research and education.\n\n\n“We are very proud to support Conquer Cancer and ASCO in their vital work accelerating breakthroughs in cancer treatment,” said Pritesh Shah, Chief Growth Officer at Novocure. “We admire and align with their unwavering commitment to improving lives through groundbreaking cancer research and education. This donation reflects our shared aspiration to make transformative progress in cancer care.\"\n\n\nASCO, the world's leading professional organization for physicians and oncology professionals caring for people with cancer, will hold its 2023 Annual Meeting in Chicago from June 2 to June 6.\n\n\n“We are grateful for Novocure’s multi-year support of cancer research and essential educational programs,” said Clifford A. Hudis, MD, FACP, FASCO, Chief Executive Officer of ASCO and Executive Vice Chair of Conquer Cancer. “This contribution will help us achieve new advances and improve the care patients receive around the world.\"\n\n\nAbout Novocure\n\n\nNovocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with g...